The AMR Action Fund is a public-private partnership investing in the development of new antimicrobial therapeutics. It focuses investments in clinical-stage companies that are developing antimicrobial therapeutics for priority pathogens, as identified by the World Health Organization (WHO) and the United States’ Centers for Disease Control and Prevention (CDC).
The Asian Development Bank (ADB)’s work in the health sector supports health infrastructure and systems, as well as governance and financing. In 2013, ADB set up the Regional Malaria and Other Communicable Disease Threats Trust Fund (RMTF) to support developing countries in the region in developing multi-country and multisector responses to malaria and other communicable disease issues.
The Department of Foreign Affairs and Trade (DFAT)’s work in health supports international development cooperation on priority health issues. Within the Global Health division of DFAT, the Indo-Pacific Centre for Health Security invests in projects in the Pacific and Southeast Asia, including a focus on infection prevention and control and antimicrobial resistance (AMR). These project investments are complemented by targeted support for the work of key multilateral organisations in the region, including the World Health Organization (WHO).
The Bill & Melinda Gates Foundation (BMGF) is a not-for-profit organisation that aims to fight poverty, disease and inequity across the world. BMGF’s Global Health Division focuses on reducing the burden of infectious diseases and the leading causes of death for women and children in developing countries.
The Clinton Health Access Initiative (CHAI) is a not-for-profit working closely with governments and the private sector to strengthen disease surveillance and data analysis, and support and scale up the delivery of preventive and therapeutic interventions, in low- and middle-income countries (LMICs). Originally focusing on HIV/AIDS, CHAI has expanded its focus to cover a host of infectious diseases, including malaria, tuberculosis, and neglected tropical diseases.
The Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) is a global not-for-profit partnership led by Boston University and funded by a consortium of governments and foundations. It is dedicated to supporting early-stage antibacterial research and development of innovative therapeutics, preventatives and rapid diagnostics for drug-resistant bacteria. CARB-X focuses investment on projects that target priority pathogens, as identified by the World Health Organization (WHO) and the United States’ Centers for Disease Control and Prevention (CDC).
The Drugs for Neglected Diseases Initiative (DNDi) is a not-for-profit research and development organisation founded by the World Health Organization (WHO) and five international research institutions. It is dedicated to the discovery, development, and delivery of affordable and patient-friendly treatments across the world, covering a range of historically neglected disease areas.
One of five EU Missions, the Mission on Cancer together with the Europe’s Beating Cancer Plan aims to provide a better understanding of cancer, allow for earlier diagnosis and optimisation of treatment and improve cancer patients’ quality of life during and beyond their cancer treatment. The Mission aims to support: an understanding of cancer, prevention and early detection, diagnosis and treatment, and quality of life for patients and their families.
Under the 2023-2024 work programme, there are no open calls for proposals.
The European Innovation Council (EIC) supports innovations with breakthrough and market-creating potential. It provides funding through open calls with no defined thematic priorities or a challenge-driven approach, focusing on a specific thematic breakthrough. EIC is divided into three different schemes: EIC Pathfinder, EIC Transition and EIC Accelerator. EIC Accelerator supports smaller actors in developing innovative solutions that would allow them to scale up.
Under the 2024 work programme, two types of calls for proposals are open: EIC Accelerator Open for projects in any field of science, technology or application without predefined thematic priorities, and EIC Accelerator Challenges for projects that match any of the predefined thematic areas of the Accelerator Challenges.
The European Innovation Council (EIC) supports innovations with breakthrough and market-creating potential. It provides funding through open calls with no defined thematic priorities or a challenge-driven approach, focusing on a specific thematic breakthrough. EIC is divided into three different schemes: EIC Pathfinder, EIC Transition and EIC Accelerator. EIC Pathfinder supports projects focusing on early-stage scientific innovation with the potential of developing scientific breakthroughs.
Under the 2024 work programme, two types of calls for proposals were planned. First, the calls under EIC Pathfinder Open, which closed in Q1 2024. Second, five calls under EIC Pathfinder Challenges for projects that match any of the predefined thematic areas of the Pathfinder Challenges, which are currently open.
The European Innovation Council (EIC) supports innovations with breakthrough and market creating potential. It provides funding through open calls with no defined thematic priorities or a challenge-driven approach, focusing on a specific thematic breakthrough. EIC is divided into three different schemes: EIC Pathfinder, EIC Transition, and EIC Accelerator. EIC Transition supports the maturation and validation of novel technology in the lab and in relevant application environments, as well as the development of a business case and business model to commercialise this novel technology.
Under the 2024 work programme, one call for proposals is currently open: EIC Transition Open. It is for projects in any field of science, technology, or application without predefined thematic priorities.
The European Investment Bank (EIB) works closely with other EU institutions to foster European integration, promote the development of the EU and support EU policies in over 160 countries around the world. It offers loans, guarantees, equity investments and advisory services to help finance large and small-scale investment projects that support EU policy objectives.
The European Partnership for Fostering a European Research Area for Health (ERA4Health) is a partnership bringing together 27 funding organisations and 33 partners from 22 countries, covering 17 of the 27 European Union (EU) Member States, 3 third countries associated to Horizon Europe (Israel, Norway, Turkey), and 2 third countries (Egypt and Taiwan). It aims to support transnational medical research across prevention, diagnosis, and treatment, capacity building and responsible research and innovation (RRI).
In 2024, two calls for proposals opened: NutriBrain, focused on modulation of brain ageing through nutrition and healthy lifestyle, and NANOTECMEC, focused on nano and advanced technologies for disease prevention, diagnostic, and therapy. The calls closed in May and June 2024, respectively; the projects are expected to start between December 2024 and May 2025.
The European Partnership on Pandemic Preparedness aims to improve the European Union’s (EU) preparedness to predict, prevent and respond to emerging infectious health threats by better coordinating funding for research and innovation at EU, national (and regional) levels.
Under the 2023-2024 work programme, three calls for proposals were expected: two to support the preparation for the partnership’s launch, which are now closed, and one to launch the partnership, which is currently open.
The European Partnership for Personalised Medicine (EP PerMed) supports synergies in research on personalised medicine across the European Union (EU) and its regional partners. The main objectives of the partnership are to (i) ensure a faster uptake of research and innovation (R&I) results into clinical practice and secure Europe’s position in state-of-the-art healthcare provision; (ii) facilitate approaches that take into account individual differences and better utilise the accumulating data to manage health, disease and its predisposition; (iii) contribute towards more sustainable healthcare systems and independence in data intensive healthcare.
Under the 2023-2024 work programme, one call for proposals was launched in 2023 and one in 2024. Both calls are now closed.
The European Partnership for Innovative SMEs (INNOVSMES) supports small- and medium-sized companies (SMEs) and project partners (such as large companies, universities and research organisations) by funding international collaborative R&D and innovation projects. By participating, organisations can increase their research and innovation (R&I) capacity, their productivity and successfully embed in global value chains and new markets. The partnership is co-funded by the European Union through Horizon Europe.
Under the 2023-2024 work programme, one call for proposals opened in 2023 and is now closed. Additionally, a joint transnational call for proposals to support Eurostars, one of the funding instruments introduced by INNOVSMES in 2021, has been published.
The One Health Antimicrobial Resistance (OH AMR) partnership aims to support the coordination and alignment of AMR research activities and funding in Europe and beyond. The main goal is to contribute to achieving the objectives of the European One Health Action Plan against AMR and the World Health Organization (WHO) Global Action Plan on AMR by reducing the threat of AMR and contributing to achieving the objectives of the Health Emergency Preparedness and Response Authority (HERA).
Under the 2023-2024 work programme, one call for proposals, launching the partnership, is currently open.
The Rare Diseases partnership aims to enhance stakeholder collaboration on rare diseases to improve the life of patients by developing treatments and diagnostics.
Under the 2023-2024 work programme, there was one call for proposal in 2023. It is now closed.
The European Partnership on Transforming Health and Care Systems (THCS) aims to support the transition towards more sustainable, resilient, innovative and high-quality people-centred health and care systems by pooling resources to tackle future health challenges.
Under the 2023-2024 work programme, there was one call for proposals. It closed in Q2 2024.
The European Research Council (ERC) supports frontier research in any field. It is open to investigators worldwide, as long as the host institution (HI) of the principal investigator that receives ERC funding is established in a Member State or a Country Associated to Horizon Europe. The ERC has four major grant programmes: Starting Grants, Consolidator Grants, Advanced Grants, and Synergy Grants.
The ERC Advanced Grant supports leading researchers with noteworthy accomplishments who wish to obtain long-term funding for ambitious research projects. The European Research Centre Advanced Grants are dedicated to experienced scientists who want to pursue groundbreaking and high-risk projects.
Under the 2024 work programme, one call for proposals is currently open.
The European Research Council (ERC) supports frontier research in any field. It is open to investigators worldwide, as long as the host institution (HI) of the principal investigator that receives ERC funding is established in a Member State or a country associated to Horizon Europe. The ERC has four major grant programmes: Starting Grants, Consolidator Grants, Advanced Grants, and Synergy Grants.
The ERC Synergy Grant supports joint projects of multiple researchers focusing on research problems that could not be solely addressed by one principal investigator.
Under the 2024 work programme, there was one call for proposals. It is now closed.
The European Research Council (ERC) supports frontier research in any field. It is open to Principal Investigators (PIs) worldwide, as long as the Host Institution (HI) of the principal investigator that receives ERC funding is established in a Member State or a country associated to Horizon Europe. The ERC has four major grant programmes: Starting Grants, Consolidator Grants, Advanced Grants, and Synergy Grants.
The ERC Consolidator Grant supports researchers with 7-12 years of experience.
Under the 2024 work programme, a call for proposals is ongoing (submission closed).
The European Research Council (ERC) supports frontier research in any field. It is open to investigators worldwide, as long as the host institution (HI) of the Principal Investigator (PI) that receives ERC funding is established in a Member State or a country associated to Horizon Europe. The ERC Proof of Concept programme supports the further development of projects funded by other ERC support programmes in an earlier stage.
Under the 2024 work programme, a call for proposals is open.
The European Research Council (ERC) supports frontier research in any field. It is open to investigators worldwide, as long as the host institution (HI) of the principal investigator that receives ERC funding is established in a Member State or a country associated to Horizon Europe. The ERC has four major grant programmes: Starting Grants, Consolidator Grants, Advanced Grants, and Synergy Grants. The ERC Starting Grant programme supports early-career scientists developing a wide range of innovative projects.
Under the 2024 work programme, there was one call for proposals. It is now closed.
The Bundesministerium für Bildung und Forschung (Federal Ministry of Education and Research) (BMBF) provides funding for research projects and institutions and has a department specifically devoted to Health Research. As part of the German Antibiotic Resistance Strategy, BMBF provides substantial support for research and development in antibiotic resistance through various funding opportunities. Key examples are the Global Antimicrobial Research and Development Hub (Global AMR R&D Hub), bringing together the European Commission, national governments, and international funding organisations, and InfectControl 2020, a research collaboration between research institutes and industrial companies.
The Global AMR Innovation Fund (GAMRIF) is UK aid fund that supports research and development around the world to reduce the threat of antimicrobial resistance in low- and middle-income countries (LMICs). GAMRIF works with a range of organisations using bilateral partnerships, global research initiatives and product development partnerships, establishing global and international research partnerships, leveraging investments from partners and donors to support sustainable partnerships for AMR, and funding projects that aim to develop solutions specifically for LMICs.
The Global Antibiotic Research and Development Partnership (GARDP) is a not-for-profit organisation developing new treatments in the area of serious bacterial infections, with a focus on children and newborns, and sexually transmitted infections, such as gonorrhoea. Established by the World Health Organization (WHO) and the Drugs for Neglected Disease Initiative (DNDi) in 2016, GARDP is a core element of WHO’s Global Action Plan on Antimicrobial Resistance.
The Global Health EDCTP3 Joint Undertaking (GH EDCTP3 JU) is a partnership between the European Union (EU) and the EDCTP Association, whose members are several European and African countries. It supports the development of new solutions for reducing the burden of infectious diseases in sub-Saharan Africa, and strengthen research capacities to prepare and respond to re-emerging infectious diseases in this region and worldwide.
Under the 2024 work programme, two calls for proposals opened: a two-stage call covering six topics for Research and Innovation Actions (RIA) and a two-stage call covering one topic for Coordination and Support Actions (CSA). All calls closed in Q1 2024.
The Global Health Innovative Technology Fund (GHIT Fund) is an international public-private partnership between the Government of Japan, multiple pharmaceutical companies, the Bill & Melinda Gates Foundation, Wellcome Trust, and United Nations Development Programme (UNDP). It facilitates global R&D partnerships for the discovery and development of new health technologies for the developing world and invests in these global R&D partnerships through a grant-making mechanism. Its portfolio covers drugs, vaccines, and diagnostics in infectious diseases, such as HIV/AIDS, malaria, tuberculosis, and neglected tropical diseases.
The Marie Skłodowska-Curie Actions (MSCA) COFUND supports regional, national and international programmes for training and career development. There are 2 types of COFUND: (i) doctoral Programmes that offer research training activities to allow doctoral candidates to develop and broaden their skills and competences, which will lead to the award of a doctoral degree; (ii) Postdoctoral Programmes, which will fund individual advanced research training and career development fellowships for postdoctoral researchers.
Under the 2023-2024 work programme, a call for proposals is currently open.
Initiative 5% is a facility implemented by the public agency Expertise France and complementing the Global Fund Initiative in building a more effective response to pandemics, with a focus on HIV/AIDS, malaria and tuberculosis, and strengthening the health impact of funded programmes for populations. Set up in 2011, it supports recipients in accessing Global Fund funding and improving the effectiveness of grants, mainly in French-speaking countries.
The Innovative Health Initiative Joint Undertaking (IHI JU) aims to foster innovation across the health industry, covering the entire cycle of healthcare, in close cooperation with industry players.
Under the 2024 work programme, a call for proposals is currently open.
Irish Aid is the Irish Government’s programme for overseas development managed by the Development Co-operation Division of the Department of Foreign Affairs. Irish Aid invests in research that focuses on improving the health of the poorest and most vulnerable communities, covering infectious diseases such as malaria and HIV, as well as vaccine development.
The Korea International Cooperation Agency (KOICA) was established in April 1991 by the Korean Government as a governmental agency dedicated to providing grant aid programs. It operates both domestically and internationally as a development cooperation platform contributing to accomplish the Sustainable Development Goals (SDGS). Through its Global Disease Eradication Fund, KOICA partners with international non-governmental organisations and the private sector to prevent and eradicate infectious diseases in developing countries.
MedAccess is a UK-based social-finance enterprise accelerating access to vaccines, medicines, diagnostics and technologies for people in underserved communities. Founded by British International Investment, MedAccess brokers and finances agreements that enable suppliers and procurers to get products to health workers and patients more quickly. Its portfolio covers HIV/AIDS and syphilis, tuberculosis, malaria, and other neglected diseases.
The Medicines for Malaria Venture (MMV) is a product development partnership (PDP) working to address unmet medical needs for key populations, such as children, pregnant women and people suffering from relapsing and drug-resistant malaria. MMV holds a large portfolio of antimalarial projects worldwide, covering all stages of product development.
The Ministerie van Buitenlandse Zaken (Ministry of Foreign Affairs) (BZ) of The Netherlands has committed to enhance its efforts in global health, having established a Dutch Global Health Strategy. The focus will be on strengthening health systems across the world and international cooperation in preparation for future pandemics.
Within the health portfolio, the Norwegian Agency for International Development Cooperation (Norad) has a mandated focus on reducing health inequities and reaching the poorest and most marginalised communities with development aid.
Open Philanthropy started as a partnership between GiveWell and Good Ventures and has operated as an independent organisation since 2017. Global Health and Wellbeing is a key focus area of Open Philanthropy investment, and includes support to research on malaria.
Research Infrastructures (RIs) aim to address global environmental, social and economic challenges by maximising science and technological contributions to meet societal needs whilst increasing the European Union’s (EU) competitiveness. RIs provide resources and services for the research communities to conduct research and foster innovation in their fields. Examples of resources and services provided include, but are not limited to equipment or sets of instruments, knowledge-related facilities, archives or scientific data infrastructures, computing systems, and communication networks.
The RIGHT Foundation is a South Korea-based public-private partnership (PPP) between the Government of Korea (GOK), Korean Life Science companies, and the Bill & Melinda Gates Foundation (BMGF). Dedicated to supporting global health R&D, it provides a platform for catalysing collaboration between Korean and international researchers to develop vaccines, treatments and diagnostics for infectious diseases (both endemic and emerging) in low- and middle-income countries (LMICs).
The Rockefeller Foundation has long been a pioneer in global health, leading campaigns to eradicate hookworm disease, malaria and yellow fever in the first half of the twentieth century, and funding research into vaccine development. Having shifted its approach in the 1970s, moving away from campaigns against a single disease towards multidisciplinary efforts, the US-based Foundation helps developing countries across the world with community health, environmental issues and other major challenges.
The Swiss Agency for Development and Cooperation (SDC) is the international cooperation agency within the Federal Department of Foreign Affairs, working with local communities across the world to promote healthy lifestyles and the prevention of noncommunicable diseases. It also supports the prevention, treatment and research on communicable diseases such as malaria, neglected tropical diseases, and HIV/AIDS.
TB Alliance is a not-for-profit product development partnership (PDP) dedicated to the discovery, development and delivery of better, faster-acting and affordable tuberculosis drugs. It holds the largest pipeline of new TB drugs in history and has advanced multiple products to market.
Unitaid is a global health agency engaged in finding innovative solutions to prevent, diagnose, and treat diseases more quickly, more affordably and effectively, in low- and middle-income countries. Their work includes funding initiatives to address diseases such as HIV/AIDS, malaria, and tuberculosis, as well as HIV co-infections and co-morbidities such as cervical cancer and hepatitis C, and cross-cutting areas, such as fever management.
The Foreign, Commonwealth and Development Office (FCDO) is the UK’s ministerial department responsible for foreign affairs and international development. A key FCDO priority is supporting research in infectious diseases, including developing new technologies and supporting health systems strengthening in low- and middle-income countries (LMICs). Among others, FCDO is working with the Bill & Melinda Gates Foundation (BMGF), CEPI, Wellcome Trust, the UK Department for Health and Social Care (DHSC), the Medical Research Council (MRC), and the WHO to drive forward the agenda on infectious disease preparedness.
The US Agency for International Development (USAID)’s global health efforts are focused on three strategic priorities: preventing child and maternal deaths, controlling the HIV/AIDS epidemic, and combating infectious diseases. Among others, the latter covers malaria, tuberculosis, neglected tropical diseases pandemic influenza.
Within the US Administration for Strategic Preparedness and Response, the Biomedical Advanced Research and Development Authority (BARDA) invests in advanced research and development, acquisition, and manufacturing of medical countermeasures needed to combat health security threats – including vaccines, drugs, therapeutics, diagnostic tools, and non-pharmaceutical products. BARDA’s active areas of interest (AOIs) include antimicrobial resistance (AMR) and influenza and emerging infectious diseases (IEID).
The US Department of Defense (DOD) works with foreign nations to establish and develop international partnerships through joint medical training exercises and public health initiatives to support and strengthen the public health capabilities of partner nations, as well as to improve interoperability. The DOD also engages with non-government organisations, academia and private-sector organisations to enhance global health objectives.
The National Institutes of Health (NIH) is the primary US federal agency conducting and supporting basic, clinical, and translational medical research. One particular area of concern within NIH’s work on infectious diseases is antimicrobial resistance (AMR) with a focus on finding new diagnostics that can quickly detect resistance and new antibiotic drugs and vaccines to prevent and treat bacterial infections.
The Wellcome Trust is an independent, global charitable foundation supporting research projects in the areas of infectious diseases, climate and health, and mental health. In the field of infectious diseases, the Trust’s focus is on developing an improved understanding of disease reservoirs, environmental zoonotic threats, and drug resistance, as well as supporting the creation of a data and surveillance architecture to better detect and improve escalation.
This tool was created by FTI Consulting for GSK and EFPIA.
For all enquiries please contact niro@fticonsulting.com
Privacy policy
This tool was created by FTI Consulting
for GSK and EFPIA.
For all enquiries please contact niro@fticonsulting.com
Privacy policy